A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. [PDF]
J Manag Care Spec Pharm, 2016 Mehta DA +5 more
europepmc +3 more sources
Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa. [PDF]
Pediatr Allergy Immunol Pulmonol, 2020 Ulusoy Severcan E +6 more
europepmc +3 more sources
Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope [PDF]
Archives of Medical Science, 2017 Xingshun Qi, Chun Ye, Xiaozhong Guo
doaj +2 more sources
Medication-Use Evaluation of Recombinant Human Factor VIIa [PDF]
Global Journal on Quality and Safety in Healthcare, 2020 Introduction: Medication-use evaluation (MUE) is a performance improvement method used to achieve optimal patient outcomes. The recombinant human factor VIIa (rFVIIa) (NovoSeven) is an expensive agent approved by the U.S.
Abrar Al-Subhi +2 more
doaj +1 more source
Dental Management of Glanzmann's Thrombasthenia in a 4-Year-Old Child With Rampant Caries: A Case Report and Literature Review. [PDF]
Clin Case RepABSTRACT Glanzmann's Thrombasthenia (GT) is a rare congenital bleeding disorder in children, caused by the absence or dysfunction of glycoprotein (GP) IIb/IIIa, a receptor located on the platelet membrane. Proper oral health and regular dental appointments are crucial for these patients. However, maintaining good oral hygiene is challenging among them.
Nazemisalman B +3 more
europepmc +2 more sources
The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection -A case report- [PDF]
Korean Journal of Anesthesiology, 2011 Little is known about the prophylactic use of recombinant factor VIIa (rFVIIa) in patients undergoing surgery for a bleeding aorta employing cardiopulmonary bypass.
Wook Jong Kim +7 more
doaj +1 more source
Use of recombinant factor VIIa in orthotopic liver transplant
Indian Journal of Anaesthesia, 2011 Pradeep Bhatia
doaj +2 more sources
Haematologica, 2015 Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon +5 more
doaj +1 more source
Factor VII deficiency-related recurrent hemarthrosis in a female child – When to suspect?
Iraqi Journal of Hematology, 2021 Recurrent hemarthrosis is a common entity in children. Although recurrent hemarthrosis most often associated with hemophilia (VIII or IX deficiency), but rarely it can be associated with factor VII deficiency (FVIID).
Siyaram Didel +4 more
doaj +1 more source
Journal of the Formosan Medical Association, 2006 Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment.
Yu-Feng Wei +4 more
doaj +1 more source